Endpoints News – Biotech, drug, pharma and health news for …
WEBThe FDA's Office of Prescription Drug Promotion sent a letter to AbbVie late last month, calling out the company for what it said was a misleading migraine drug tele ...
About Endpoints News – Endpoints News
WEBJohn D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 20 years. Aside from ...
Weekly channel feed - Endpoints News
WEBNvidia's biotech moment; Regeneron launches venture arm; New GLP-1 player enters; Sanofi rejigs cancer pact, vaccine ops; and more. 4 months ago.
ESMO23 | Cancer breakthroughs and barriers in oncology R&D
WEBAfter a decade of patient breakthroughs leveraging technologies like immunotherapy, ADCs and targeted therapies, cancer R&D is staring down its next era. Our expert panel will look at how the R&D landscape has shifted, new attempts to go after cancer's “undruggable” targets and how the field is thinking about where the goalposts are in what ...
Endpoints News – The biopharma world is here
WEBEndpoints News – The biopharma world is here. Get the latest reports on drug development, clinical trials, deals and more from the industry experts.
Endpoints at #JPM22 - A look at what's to come in 2022
WEBEndpoints has been there to chronicle it with wall-to-wall coverage, and our founder and editor John Carroll has convened top newsmakers to provide detailed insights about their strategies. For #JPM22, Endpoints is expanding on our proud tradition with multiple panels addressing the most important issues in biopharma R&D. title sponsor.
Endpoints at #JPM24 | Primed to unlock biopharma's next …
WEBJoin Endpoints on Monday as we sit down with leading minds in research, investing and deal making. Our Monday sessions will feature some of pharma’s top M&A execs, a view from the top at one of biotech’s creation engines, a candid look at the capital raising process at two up-and-coming companies and inside perspectives from the activist and M&A world.
Endpoints News — Pfizer takes pivotal RSV vaccine data to the …
WEBby Zachary Brennan: The 50-year race to develop an RSV vaccine turned a corner on Thursday with Pfizer unveiling promising pivotal data for its bivalent RSV vaccine candidate, promising to take the data to the FDA ahead of several rivals in a market that could stretch to $10 billion by 2030.
Novartis’ Kisqali snags FDA approval to reduce recurrence in …
WEB3 hours ago · Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast cancer market. The FDA approved the oral treatment Tuesday for patients ...
Endpoints at #ASH22 - Cell & gene therapies are headed to critical ...
WEB12 Dec. 12:30 - 1:30pm ET. (9:30 - 10:30 local time) An Endpoints News team led by managing editor Kyle Blankenship will report on all the top news out of the world’s premier cell and gene therapy science conference held virtually and in Atlanta this year. Blankenship will follow the news coverage with an online panel discussion on what ...
Skip to content